Arrowhead Research Corp  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for Arrowhead Systems, Inc.�
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.95 - 17.42
Open     -
Vol / Avg. 0.00/1.63M
Mkt cap 372.46M
P/E     -
Div/yield     -
EPS -1.56
Shares 59.50M
Beta 2.18
Inst. own 55%
Aug 10, 2015
Q3 2015 Arrowhead Research Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2015
Q2 2015 Arrowhead Research Corp Earnings Call - Webcast
May 11, 2015
Q2 2015 Arrowhead Research Corp Earnings Release
May 7, 2015
Arrowhead Research Corp at Deutsche Bank Health Care Conference
Mar 11, 2015
Arrowhead Research Corp at Barclays Healthcare Conference - Webcast
Mar 5, 2015
Arrowhead Research Corp Conference Call to Discuss the acquisition of Novartis' RNAi Research and Development Portfolio - Webcast
Mar 3, 2015
Arrowhead Research Corp Annual Shareholders Meeting
Feb 24, 2015
Arrowhead Research Corp at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -65563.41% -33557.38%
Operating margin -67731.98% -30443.59%
EBITD margin - -28433.29%
Return on average assets -70.91% -53.35%
Return on average equity -79.07% -60.43%
Employees 81 -
CDP Score - -


Suite 1050, 225 South Lake Avenue
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company’s drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Officers and directors

Douglass B. Given M.D., Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
David Lewis Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Susan Boynton Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Peter Brian Leone Vice President-Strategy & Program Management
Age: 58
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 51
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D Independent Director
Age: 55
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 78
Bio & Compensation  - Reuters